Oral Orexin-1 Antagonist
The Orexin-1 receptor is considered to be central to the brain’s ‘craving’ and ‘reward’ pathways with pre-clinical efficacy observed in multiple addiction models. However, to date no drug candidate that targets Orexin-1 has progressed into clinical development, in large part due to the difficulty in identifying candidates that are specific only to Orexin-1. Orexin-2 has high structural similarity to Orexin-1, but has a very different biological function. Orexin-2 is targeted in the treatment of insomnia, and it has historically proved highly challenging to develop drug candidates which will target Orexin-1 selectively without targeting Orexin-2.